1. Claudia A. Chiriboga-Klein, MD, MPH

    • Department of Neurology
      Division of Child Neurology
    • Department of Pediatrics
    Headshot

    Dr. Chiriboga is Associate Professor of Clinical Neurology and Pediatrics of the Division of Pediatric Neurology, Departments of Neurology and Pediatrics, College of Physicians and Surgeons of Columbia University and Chief of Pediatric Neurology at Columbia University's affiliate hospital, Harlem Hospital Center.

    Dr. Chiriboga was born in Peru and educated in Argentina, where she graduated with Honors from the Faculty of Medicine at the National University of Buenos Aires in 1982. Dr. Chiriboga completed training in pediatrics at St. Luke's-Roosevelt Hospital in 1985. After completing her training in child neurology in 1988 at the Neurological Institute and Babies Hospital of Columbia-Presbyterian Medical Center, Dr. Chiriboga joined the Division of Pediatric Neurology at Columbia Presbyterian Medical Center. Subsequently, she completed a Neuroepidemiology fellowship at Sergievsky Center and received a Master in Public Health from the Mailman School of Public Health, Columbia University. Dr. Chiriboga serves/has served on committees of the NIH, CNS, and ABPN, and is a regular examiner for the Part II ABPN examination. She is a diplomate of the ABPN in child neurology.

    CUMC crown logoClaudia A. Chiriboga-Klein, MD, MPH
    is accepting new patients.
    Call (212) 342-6867 for appointments.

    Provider Information

    One of America's Top Doctors
    One of America's Top Doctors.
    Rated one of New York Magazine's Best Doctors
    Rated One of New York Magazine's
    Best Doctors.

    Board Certifications

    • Child Neurology
    • Neurology With Special Qualifications In Child Neurology

    Clinical Expertise

    • Developmental Disorder
    • Headache
    • Migraines
    • Movement Disorder

    Hospital Affiliations

    • NewYork-Presbyterian/Columbia
    • NewYork-Presbyterian/Morgan Stanley Children's Hospital

    Primary Location

    • Harkness Pavilion

      180 Fort Washington Avenue
      Suite: 552
      New York, NY 10032
      Phone:
      (212) 305-8549
      For new and current patient appointments, call:
      (212) 342-6867
      Fax:
      (212) 342-6865

    Insurance Programs

    Please contact the provider’s office directly to verify that your particular insurance is accepted.
    • Aetna [EPO, HMO, Medicare, NY Signature, POS, PPO, Signature Administrators, Student Health]
    • Affinity [Access (Exchange), Essential Plan, Medicaid Managed Care, Medicare Managed Care]
    • Amida Care
    • Cigna [EPO, Great West, HMO, POS, PPO]
    • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
    • Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
    • Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
    • Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
    • Healthfirst [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
    • Local 1199
    • MagnaCare
    • Medicare [Medicare]
    • Multiplan
    • Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
    • POMCO
    • UnitedHealthcare [Columbia University Employee Plan, EPO, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
    • VNSNY CHOICE [SelectHealth]

    Biographical Detail

    Academic Appointments

    • Professor of Neurology and Pediatrics (in the Gertrude H. Sergievsky Center) at CUMC

    Education And Training

      Education & Training

    • University of Buenos Aires Medical School
    • Residency: St Lukes Roosevelt Hospital
    • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center

    Gender

    Female

    Languages Spoken

    • Spanish
  2. Dr. Chiriboga's clinical research, including NIH funding, has focused on congenital infections and neurodevelopmental disorders, including cerebral palsy and effects of perinatal exposures. Her clinical practice focuses on developmental, neurobehavioral neurology and migraine and on the treatment of spasticity.

    Research Information

    Grants/Contracts

    • A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-PROCEDURE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF ISIS 396443 ADMINISTERED INTRATHECALLY IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)

      Nov 14 2014 - Nov 14 2019

      A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-PROCEDURE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF ISIS 396443 ADMINISTERED INTRATHECALLY IN PATIENTS WITH INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)

      Aug 14 2014 - Aug 14 2019

      AN OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF ISIS 396443 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY WHO PREVIOUSLY PARTICIPATED IN ISIS 396443-CS2 OR ISIS 396443-CS10 (P&S Industry Clinical Trial)

      Jan 23 2014 - Jan 23 2019

      SPINAL MUSCULAR ATROPHY (SMA) BIOMARKERS IN THE IMMEDIATE POSTNATAL PERIOD OF DEVELOPMENT NN101 (Federal Gov)

      Sep 30 2011 - Aug 31 2018

      SPINAL MUSCULAR ATROPHY (SMA) BIOMARKERS IN THE IMMEDIATE POSTNATAL PERIOD OF DEVELOPMENT NN101 (Federal Gov)

      Sep 30 2011 - Aug 31 2018

      COLUMBIA UNIVERSITY MEDICAL CENTER-WEILL CORNELL MEDICAL CENTER NEXT SITE (Federal Gov)

      Sep 30 2011 - Jun 30 2018

      A STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF ISIS 396443 DELIVERED INTRATHECALLY TO PATIENTS WITH INFANTILE-ONSET SPINAL MUSCULAR ATROPHY. (P&S Industry Clinical Trial)

      Jun 4 2013 - Jun 4 2018

      AN OPEN-LABEL, DOSE ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY AND DOSE-RANGE FINCING OF MULTIPLE DOSES OF ISIS 396443 DELIVERD INTRATHECALLY TO PATIENTS WITH SMA. (P&S Industry Clinical Trial)

      Mar 14 2013 - Mar 14 2018

      ANOPEN LABEL, ESCALATING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND DOSE RANGE FINDING OF MULTIPLE INTRATHECAL DOSES OF ISIS 396443 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)

      Oct 25 2012 - Oct 25 2017

      ISIS (P&S Industry Clinical Trial)

      Dec 2 2011 - Dec 2 2016

      SMA FOUNDATION CENTER GRANT (Private)

      Jul 1 2015 - Dec 31 2015

      PEDIATRIC NEUROMUSCULAR CLINICAL RESEARCH NETWORK FOR SMA (Private)

      Jul 1 2012 - Jun 30 2015

      COLUMBIA SMA PROJECT: 4-AP AS A POTENTIAL SMA THERAPEUTIC AGENT AND BIOLOGICAL MECHANISMS OF ACTION (Federal Gov)

      Sep 1 2011 - Aug 31 2014

  3. publications

    For a complete list of publications, please visit PubMed.gov